

(Please amend the following claims:)

1 ✓ 8. (Five Times Amended) An isolated tumor antigen protein selected from the group consisting of:

(a) a protein comprising an amino acid sequence shown in SEQ ID NO:2; and

(b) a protein encoded by a DNA comprising a nucleotide sequence shown in SEQ ID NO:1,

G¹ wherein said protein yields, through intracellular decomposition, peptide fragment(s) which binds to major histocompatibility complex (MHC) class I antigen and is recognized by tumor-specific cytotoxic T lymphocytes (CTLs) in such binding state.

2 ✓ 9. (Four Times Amended) An isolated and chemically synthesized tumor antigen peptide that is a peptide fragment of a tumor antigen protein selected from the group consisting of:

G² (a) a protein comprising an amino acid sequence shown in SEQ ID NO:2; and

(b) a protein encoded by a DNA comprising a nucleotide sequence shown in SEQ ID NO:1,

wherein said tumor antigen peptide comprises the amino acid sequence of positions 749-757, 736-744, 785-793, or 690-698 in the

Appl. No. 09/202,047

G²_{cl} amino acid sequence of SEQ ID NO:2, and binds to MHC class I antigen and is recognized by tumor-specific CTLs when bound to MHC class I antigen.

Attached hereto is a marked up version showing the changes made to the application by this Amendment.

3

Claim 8 (Amended)

A composition comprising, as an active ingredient, the tumor antigen protein of claim ¹/₈.

Claim ⁴/₁₂ (Amended)

A composition comprising, as an active ingredient, the tumor antigen peptide of claim ²/₁₁.

Claim 13 (Amended)

A composition comprising, as an active ingredient, the tumor antigen peptide of claim 8.
